4.6 Article

Potential 18F-RGD PET/CT and DCE-MRI Imaging-Based Biomarkers for Postoperative Survival Prediction Among Patients With Newly Diagnosed Glioblastoma Treated With Bevacizumab and Chemoradiotherapy

期刊

FRONTIERS IN ONCOLOGY
卷 12, 期 -, 页码 -

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.848266

关键词

Glioblastoma; F-18-RGD PET; CT; DCE-MRI; bevacizumab; concurrent radiotherapy and temozolomide; PFS; OS

类别

资金

  1. Natural Science Foundation of China
  2. Shandong Key Research and Development Plan [NSFC81872475, NSFC82073345]
  3. Research Unit of Radiation Oncology, Chinese Academy of Medical Sciences [2017CXGC1209]
  4. Academic Promotion Program of Shandong First Medical University [2019RU071]
  5. foundation of National Natural Science Foundation of China [2019ZL002]
  6. foundation of Natural Science Foundation of Shandong [81627901, 81972863, 82030082]
  7. Roche Ltd. [ZR201911040452]

向作者/读者索取更多资源

This study investigates the ability of F-18-AlF-NOTA-PRGD2 positron emission tomography/computed tomography (F-18-RGD PET/CT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to predict the response to bevacizumab combined with conventional therapy in newly diagnosed glioblastoma patients. The results show that a greater decrease in SUVmean predicts better progression-free survival (PFS), while a small decrease in K-trans predicts improved overall survival (OS).
PurposeTo investigate the ability of potential imaging biomarkers based on F-18-AlF-NOTA-PRGD2 positron emission tomography/computed tomography (F-18-RGD PET/CT) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) imaging to predict the response to bevacizumab combined with conventional therapy in postoperative newly diagnosed glioblastoma. MethodsTwenty patients with newly diagnosed with glioblastoma after surgery were prospectively enrolled to receive bevacizumab plus conventional concurrent radiotherapy and temozolomide (CCRT). F-18-RGD PET/CT and DCE-MRI were performed at baseline, week 3, and week 10 for each patient. Statistical methods included the analysis of variance (ANOVA), Kaplan-Meier method and Cox proportional hazard analysis. ResultsAll patients completed CCRT plus bevacizumab therapy without interruption. The median follow-up time was 33.9 months (95% confidence interval [CI], 28.3-39.5 months). The median progression-free survival (PFS) and overall survival (OS) was 9.66 months (95% CI, 6.20-13.12 months) and 15.89 months (95% CI, 13.89-17.78), respectively. Treatment was generally well tolerated, and there were no Treatment emergent adverse events (TEAEs) with a toxicity grade equal to or exceeding 3 or that led to termination of treatment or patient death.Over the treatment interval of bevacizumab therapy from week 3 to week 10, patients with a large decrease of SUVmean was associated with a better PFS with a hazard ratio (HR) of 6.562, 95% CI (1.318-32.667), p=0.022. According to Kaplan-Meier analysis, patients with a decrease in the SUVmean of more than 0.115 on F-18-RGD PET/CT had a longer PFS than those with a decrease in the SUVmean of 0.115 or less (12.25 months vs.7.46 months, p=0.009). For OS, only a small decrease of Ktrans was also found to have certain prognostic value (HR=0.986, 95% CI (0.975-0.998), p=0.023). Patients with a decrease in Ktrans larger than 37.03 (min-1) on DCE-MRI had worse OS than those with a decrease in Ktrans of 37.03 (min-1) or less (15.93 months vs. 26.42 months, p=0.044). Conclusion(18)F-RGD PET/CT and DCE-MRI may be valuable in evaluating the response of glioblastoma to treatment with the combination of bevacizumab and CCRT, with a greater decrease in SUVmean predicting better PFS as well as a small decrease in K-trans predicting improved OS.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据